Nevrargenics Ltd is a UK-based neuroscience company (spin out of Durham university chemistry department, CEO Professor Andy Whiting) specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer’s, Parkinson’s, Multiple Sclerosis, Motor neuron disease (MND), and other neurological and psychiatric diseases.
With an estimated nearly 1 billion sufferers* and characterised by progressive neuronal loss, neurodegeneration leads to broad range of clinical manifestations typically associated with severe motor disability, cognitive and mental health decline and/or dementia (UN Report, 2007). Research groups based at Aberdeen and Durham Universities, and recently Kings college London and Liverpool, have been collaborating for several years, and through this collaboration, have designed, synthesized and identified a lead drug candidate with the potential for establishing new treatment approaches. Our strategy is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a series of new rationally designed, effective treatments, meeting that most severe of unmet needs. Earlier this week, the Scientific Advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was held to discuss Nevrargenics’ MND drug candidate, NVG0645 (now called Ellorarxine). The good news is that the MHRA has formally approved the clinical programme progression plan to take Ellorarxine to the clinic for MND in 2024.
/prod01/prodbucket01/media/durham-university/research-/research-institutes/wolfson-research-institute/60056.jpg)